815 related articles for article (PubMed ID: 29202397)
21. Quinazolin-4(3H)-one-Based Hydroxamic Acids: Design, Synthesis and Evaluation of Histone Deacetylase Inhibitory Effects and Cytotoxicity.
Hieu DT; Anh DT; Hai PT; Thuan NT; Huong LT; Park EJ; Young Ji A; Soon Kang J; Phuong Dung PT; Han SB; Nam NH
Chem Biodivers; 2019 Apr; 16(4):e1800502. PubMed ID: 30653817
[TBL] [Abstract][Full Text] [Related]
22. Synthesis, Biological Evaluation, and Computer-Aided Drug Designing of New Derivatives of Hyperactive Suberoylanilide Hydroxamic Acid Histone Deacetylase Inhibitors.
Zhang S; Huang W; Li X; Yang Z; Feng B
Chem Biol Drug Des; 2015 Oct; 86(4):795-804. PubMed ID: 25763653
[TBL] [Abstract][Full Text] [Related]
23. Anti-tumor activity evaluation of novel tubulin and HDAC dual-targeting inhibitors.
Wang B; Chen X; Gao J; Su L; Zhang L; Xu H; Luan Y
Bioorg Med Chem Lett; 2019 Sep; 29(18):2638-2645. PubMed ID: 31400938
[TBL] [Abstract][Full Text] [Related]
24. Design, synthesis and docking studies on benzamide derivatives as histone deacetylase inhibitors.
Lu A; Luo H; Shi M; Wu G; Yuan Y; Liu J; Tang F
Bioorg Med Chem Lett; 2011 Aug; 21(16):4924-7. PubMed ID: 21741834
[TBL] [Abstract][Full Text] [Related]
25. Discovery of meta-sulfamoyl N-hydroxybenzamides as HDAC8 selective inhibitors.
Zhao C; Zang J; Ding Q; Inks ES; Xu W; Chou CJ; Zhang Y
Eur J Med Chem; 2018 Apr; 150():282-291. PubMed ID: 29533873
[TBL] [Abstract][Full Text] [Related]
26. Novel HDAC/Tubulin Dual Inhibitor: Design, Synthesis and Docking Studies of α-Phthalimido-Chalcone Hybrids as Potential Anticancer Agents with Apoptosis-Inducing Activity.
Mourad AAE; Mourad MAE; Jones PG
Drug Des Devel Ther; 2020; 14():3111-3130. PubMed ID: 32848361
[TBL] [Abstract][Full Text] [Related]
27. Design, synthesis and biological evaluation of novel coumarin-based benzamides as potent histone deacetylase inhibitors and anticancer agents.
Abdizadeh T; Kalani MR; Abnous K; Tayarani-Najaran Z; Khashyarmanesh BZ; Abdizadeh R; Ghodsi R; Hadizadeh F
Eur J Med Chem; 2017 May; 132():42-62. PubMed ID: 28340413
[TBL] [Abstract][Full Text] [Related]
28. Design and synthesis of a new generation of substituted purine hydroxamate analogs as histone deacetylase inhibitors.
Liu R; Wang J; Tang W; Fang H
Bioorg Med Chem; 2016 Apr; 24(7):1446-54. PubMed ID: 26907204
[TBL] [Abstract][Full Text] [Related]
29. Thioether-based 2-aminobenzamide derivatives: Novel HDAC inhibitors with potent in vitro and in vivo antitumor activity.
Yun F; Cheng C; Ullah S; He J; Zahi MR; Yuan Q
Eur J Med Chem; 2019 Aug; 176():195-207. PubMed ID: 31103900
[TBL] [Abstract][Full Text] [Related]
30. Design, synthesis and anticancer potential of NSC-319745 hydroxamic acid derivatives as DNMT and HDAC inhibitors.
Yuan Z; Sun Q; Li D; Miao S; Chen S; Song L; Gao C; Chen Y; Tan C; Jiang Y
Eur J Med Chem; 2017 Jul; 134():281-292. PubMed ID: 28419930
[TBL] [Abstract][Full Text] [Related]
31. Design, Multicomponent Synthesis, and Anticancer Activity of a Focused Histone Deacetylase (HDAC) Inhibitor Library with Peptoid-Based Cap Groups.
Krieger V; Hamacher A; Gertzen CGW; Senger J; Zwinderman MRH; Marek M; Romier C; Dekker FJ; Kurz T; Jung M; Gohlke H; Kassack MU; Hansen FK
J Med Chem; 2017 Jul; 60(13):5493-5506. PubMed ID: 28574690
[TBL] [Abstract][Full Text] [Related]
32. Design, Synthesis and Biological Evaluation of New HDAC1 and HDAC2 Inhibitors Endowed with Ligustrazine as a Novel Cap Moiety.
Al-Sanea MM; Gotina L; Mohamed MF; Grace Thomas Parambi D; Gomaa HAM; Mathew B; Youssif BGM; Alharbi KS; Elsayed ZM; Abdelgawad MA; Eldehna WM
Drug Des Devel Ther; 2020; 14():497-508. PubMed ID: 32103894
[TBL] [Abstract][Full Text] [Related]
33. Development of hydroxamate-based histone deacetylase inhibitors containing 1,2,4-oxadiazole moiety core with antitumor activities.
Yang F; Shan P; Zhao N; Ge D; Zhu K; Jiang CS; Li P; Zhang H
Bioorg Med Chem Lett; 2019 Jan; 29(1):15-21. PubMed ID: 30455152
[TBL] [Abstract][Full Text] [Related]
34. Alkoxyurea-Based Histone Deacetylase Inhibitors Increase Cisplatin Potency in Chemoresistant Cancer Cell Lines.
Stenzel K; Hamacher A; Hansen FK; Gertzen CGW; Senger J; Marquardt V; Marek L; Marek M; Romier C; Remke M; Jung M; Gohlke H; Kassack MU; Kurz T
J Med Chem; 2017 Jul; 60(13):5334-5348. PubMed ID: 28581289
[TBL] [Abstract][Full Text] [Related]
35. Design and synthesis of novel 1,2,3-triazole-dithiocarbamate hybrids as potential anticancer agents.
Duan YC; Ma YC; Zhang E; Shi XJ; Wang MM; Ye XW; Liu HM
Eur J Med Chem; 2013 Apr; 62():11-9. PubMed ID: 23353743
[TBL] [Abstract][Full Text] [Related]
36. Design, synthesis and anticancer activity of novel valproic acid conjugates with improved histone deacetylase (HDAC) inhibitory activity.
Ibrahim TS; Sheha TA; Abo-Dya NE; AlAwadh MA; Alhakamy NA; Abdel-Samii ZK; Panda SS; Abuo-Rahma GEA; Mohamed MFA
Bioorg Chem; 2020 Jun; 99():103797. PubMed ID: 32247939
[TBL] [Abstract][Full Text] [Related]
37. Design, Synthesis and Biological Evaluation of Novel Coumarin-Based Hydroxamate Derivatives as Histone Deacetylase (Hdac) Inhibitors with Antitumor Activities.
Yang F; Zhao N; Song J; Zhu K; Jiang CS; Shan P; Zhang H
Molecules; 2019 Jul; 24(14):. PubMed ID: 31311163
[TBL] [Abstract][Full Text] [Related]
38. Design, synthesis, and preliminary bioactivity evaluation of N-benzylpyrimidin-2-amine derivatives as novel histone deacetylase inhibitor.
Zhou Y; Dun Y; Fu H; Wang L; Pan X; Yang X; Fang H
Chem Biol Drug Des; 2017 Nov; 90(5):936-942. PubMed ID: 28489276
[TBL] [Abstract][Full Text] [Related]
39. Design, synthesis and evaluation of novel HDAC inhibitors as potential antitumor agents.
Cheng J; Qin J; Guo S; Qiu H; Zhong Y
Bioorg Med Chem Lett; 2014 Oct; 24(19):4768-4772. PubMed ID: 25182565
[TBL] [Abstract][Full Text] [Related]
40. Design, synthesis, and biological evaluation of indole-based hydroxamic acid derivatives as histone deacetylase inhibitors.
Jiang BE; Hu J; Liu H; Liu Z; Wen Y; Liu M; Zhang HK; Pang X; Yu LF
Eur J Med Chem; 2022 Jan; 227():113893. PubMed ID: 34656899
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
